Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H28Cl2F2N2O4S |
Molecular Weight | 609.511 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(O)C1=CN(C(=N1)C(C)(C)C2=C(Cl)C=CC=C2Cl)C3=CC=C(C=C3F)C4=CC(=C(CO)C(F)=C4)S(C)(=O)=O
InChI
InChIKey=HNAJDMYOTDNOBK-UHFFFAOYSA-N
InChI=1S/C29H28Cl2F2N2O4S/c1-28(2,26-19(30)7-6-8-20(26)31)27-34-25(29(3,4)37)14-35(27)23-10-9-16(11-22(23)33)17-12-21(32)18(15-36)24(13-17)40(5,38)39/h6-14,36-37H,15H2,1-5H3
Molecular Formula | C29H28Cl2F2N2O4S |
Molecular Weight | 609.511 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:26 GMT 2023
by
admin
on
Sat Dec 16 11:40:26 GMT 2023
|
Record UNII |
H9649L8MZN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000042392
Created by
admin on Sat Dec 16 11:40:26 GMT 2023 , Edited by admin on Sat Dec 16 11:40:26 GMT 2023
|
PRIMARY | |||
|
1256918-39-4
Created by
admin on Sat Dec 16 11:40:26 GMT 2023 , Edited by admin on Sat Dec 16 11:40:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545047
Created by
admin on Sat Dec 16 11:40:26 GMT 2023 , Edited by admin on Sat Dec 16 11:40:26 GMT 2023
|
PRIMARY | |||
|
49787490
Created by
admin on Sat Dec 16 11:40:26 GMT 2023 , Edited by admin on Sat Dec 16 11:40:26 GMT 2023
|
PRIMARY | |||
|
H9649L8MZN
Created by
admin on Sat Dec 16 11:40:26 GMT 2023 , Edited by admin on Sat Dec 16 11:40:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Drugs: BMS 852927(Primary), HMG-CoA reductase inhibitors; Indication: Hypercholesterolaemia; Focus: Adverse reactions, Therapeutic Use; Most Recent Events: 01 Jun 2013 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov record., 01 Aug 2012 New trial record
|
||
|
ACTIVE MOIETY |
BMS-852927 (formerly XL041); Company: Exelixis Inc.; Description: Small molecule modulator of the Liver X receptor (LXR); Molecular Target: Liver X receptor (LXR); Therapeutic Modality: Small molecule; Latest Stage of Development: Phase I; Standard Indication: Metabolic syndrome; Indication Details: Treat metabolic syndrome; Partner: Bristol-Myers Squibb Co.
|